Home / Market News / $AQST
benzinga Corporate Catalyst Impact 85/100 ● neutral

FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027

Oct 15, 2026, 11:15 AM UTC · Primary ticker $AQST

Aquestive Therapeutics announced the FDA accepted its Anaphylm NDA resubmission as complete, setting a PDUFA goal date of March 16, 2027. This is a significant positive development for the company, as it moves closer to potential approval for a first-in-class oral treatment for anaphylaxis.

Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm, classifying it as a Class 2 response and setting a PDUFA goal date of March 16, 2027. This is a crucial step forward for AQST, as it indicates the FDA is actively reviewing the application for a potential first-in-class oral treatment for anaphylaxis, addressing previous concerns. The market will likely react positively to this news, as it reduces uncertainty and provides a clear timeline for a potential approval. Short-term, this could lead to increased investor confidence and a bump in stock price. Long-term, successful approval would open up a significant market opportunity for AQST, potentially disrupting the current standard of care for anaphylaxis treatment. The key opportunity for traders is the potential for further upside as the PDUFA date approaches, assuming no further delays or negative news.

$AQST positive NDA resubmission accepted, PDUFA date set
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.